Female sex hormone helps protect against hearing loss

Our hearing is one of the wonders of the human body which is all too often taken for granted. Like many things in life, we don't really appreciate our ability to hear clearly until we begin to lose it. As we age, our ability to discern sounds begins to deteriorate. Therefore, new innovative therapies to guard the hearing of patients are eagerly sought after. Sometimes these treatments can come from unexpected sources, such as the 'female sex hormone' estradiol.

A team of researchers from Sweden's prestigious Karolinska Institute studied the role of estradiol in hearing loss recovery by examining mice with deficiencies in various estrogen receptors. They found that mice of both sexes deficient in only one estrogen receptor had reduced recovery from auditory trauma and that treatment with estrogen receptor drugs protected the animals against auditory damage. Their findings have recently been published in the Journal of Clinical Investigation (JCI).

Estradiol is a sex hormone, which although labeled 'female', is found in both men and women. In women, estradiol acts as a growth hormone for tissue of the reproductive organs and plays a critical role in sexual development. In men, the hormone is generated in testosterone by aromatase, a protein which is found throughout the male reproductive system and shares in the development of sperm.

In addition to the critical role it plays in reproductive and sexual functioning, Estradiol is also known to affect other organs. Not only does it regulate bone formation and cardiovascular tone in elderly men, the hormone is known to help maintain cell survival within the central nervous system of both sexes.

Previous clinical and experimental studies have also indicated that estradiol plays a significant role in auditory physiology. In women, it was found that hearing thresholds vary with sex hormone levels during the menstrual cycle, and postmenopausal women have higher auditory brainstem response (ABR) thresholds than younger women or men. These studies indicate a protective function of estradiol in the female auditory system.

However, until now, little was known about the impact of estradiol-binding proteins known as estrogen receptors (ERs) on hearing or whether there are sex specific facets in the inner ear. In this latest investigation, the scientists from the Karolinska Institute examined the role of known estrogen receptors in response to auditory damage. This was done by testing hearing loss recovery in mice that had deficiencies in various estrogen receptors.

Researchers found that mice only lacking in the estrogen receptor ER-beta recovered less well from hearing loss. They also discovered that treatment with ER-beta-binding drugs protected mice from auditory damage. In addition, not only was ER-beta found in the ears of mice of both sexes, but levels of brain-derived neurotrophic factor (BDNF), a protein which protects nerves, were found to be lower in mice that lacked either ER-beta or aromatase.

These findings are the first experimental evidence directly linking ER expression to the protection of auditory function.The researchers involved in the study are confident that their findings will now pave the way for the development of new treatments against hearing loss.

For further information, please visit:
http://jci.org

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...